High-throughput methods for the analysis of transcription factors and chromatin modifications: Low input, single cell and spatial genomic technologies
M Salma, C Andrieu-Soler, V Deleuze… - Blood Cells, Molecules …, 2023 - Elsevier
Genome-wide analysis of transcription factors and epigenomic features is instrumental to
shed light on DNA-templated regulatory processes such as transcription, cellular …
shed light on DNA-templated regulatory processes such as transcription, cellular …
Acute Erythroid Leukemia: From Molecular Biology to Clinical Outcomes
P Fernandes, N Waldron, T Chatzilygeroudi… - International Journal of …, 2024 - mdpi.com
Acute Erythroid Leukemia (AEL) is a rare and aggressive subtype of Acute Myeloid
Leukemia (AML). In 2022, the World Health Organization (WHO) defined AEL as a biopsy …
Leukemia (AML). In 2022, the World Health Organization (WHO) defined AEL as a biopsy …
HDAC7 is a potential therapeutic target in acute erythroid leukemia
W Zhang, K Yamamoto, YH Chang, T Yabushita, Y Hao… - Leukemia, 2024 - nature.com
Acute erythroleukemia (AEL) is a rare subtype of acute myeloid leukemia with a poor
prognosis. In this study, we established a novel murine AEL model with Trp53 depletion and …
prognosis. In this study, we established a novel murine AEL model with Trp53 depletion and …
[HTML][HTML] 骨髓红系比例≥ 50% 的骨髓增生异常综合征患者临床特征及预后分析
曾燕平， 李冰， 秦铁军， 徐泽锋， 曲士强… - Chinese Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
目的分析骨髓红系比例≥ 50% 的骨髓增生异常综合征(MDS-E) 患者临床和实验室特征及预后.
方法收集2014 年5 月至2023 年6 月于中国医学科学院血液病医院确诊的1 436 例MDS …
方法收集2014 年5 月至2023 年6 月于中国医学科学院血液病医院确诊的1 436 例MDS …
HDAC7 is a specific therapeutic target in Acute Erythroid Leukemia
S Goyama, W Zhang, K Yamamoto, YH Chang… - 2024 - researchsquare.com
Acute erythroleukemia (AEL) is a rare subtype of acute myeloid leukemia with a poor
prognosis. In this study, we established a novel murine AEL model with Trp53 depletion and …
prognosis. In this study, we established a novel murine AEL model with Trp53 depletion and …
NFIA-ETO2, TP53, and erythroid leukemogenesis
6. Eichhorst B, Niemann C, Kater AP, et al. A randomized phase III study of venetoclaxbased
time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy …
time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy …